Purpose: To assess possible changes in medication adherence to prostaglandin analog (PGA) regimens among patients with open-angle glaucoma (OAG) after the initial introduction of generic PGAs.
Design: Longitudinal cohort analysis.
Participants: Patients older than 40 years with OAG continuously enrolled in a nationwide managed-care network during 2009-2012 who used PGAs.
Methods: Mean adherence rates were calculated for topical PGA use during the 18 months before the introduction of generic latanoprost (September 2009-February 2011) and the 18 months after generic latanoprost became available (July 2011-December 2012). The rates were compared between persons who continued to use brand-name PGAs once generic latanoprost became available and others who switched to generic latanoprost. Multivariable logistic regression identified variables associated with an improvement or worsening of adherence of ≥25%.
Main Outcome Measures: Mean adherence rates and odds of 25% or more improved or worsened adherence (with 95% confidence intervals [CIs]).
Results: A total of 8427 patients met the study eligibility criteria. Compared with persons switching to generic latanoprost, patients who continued taking brand name PGAs were 28% less likely to have improved adherence (odds ratio [OR], 0.72; 95% CI, 0.55-0.94) and 39% more likely to have reduced adherence (OR, 1.39; 1.04-1.86) of ≥25%. Improved adherence after the generic drug's introduction was also associated with higher monthly medication copay in the pregeneric period (P = 0.02), lower copay after introduction of the generic drug (P < 0.0001), and black race (OR, 1.25; 95% CI, 1.04-1.50). Six-hundred twelve patients (7.3%) discontinued all antiglaucoma interventions when generic latanoprost became available.
Conclusions: Given that cost can significantly deter adherence, switching patients to generic medications may help improve patients' drug-regimen adherence. A considerable number of patients discontinued glaucoma drug use altogether when generic latanoprost became available. Ophthalmologists should work with insurers and pharmacists to prevent such discontinuation of use as generic forms of other PGA agents become available.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518849 | PMC |
| http://dx.doi.org/10.1016/j.ophtha.2014.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.
BMC Ophthalmol
December 2024
Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Background: Prostaglandin analogs are first-line treatments for open-angle glaucoma due to their proven efficacy in reducing intraocular pressure. Despite their topical administration, systemic adverse drug Events (ADEs) have been reported. This study investigates the systemic ADEs associated with topical prostaglandin analogs using the United States Food and Drug Administration (USFDA) Adverse Drug Event Reporting System (AERS) database.
View Article and Find Full Text PDFAdverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.
Ther Adv Drug Saf
October 2024
Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, 401 Chengyi Build, Xiang-an Campus of Xiamen University, South Xiang-an Road, Xiamen, Fujian 361005, China.
Article Synopsis
- - The study investigates common adverse events related to four prostaglandin medications used for glaucoma (latanoprost, bimatoprost, travoprost, and tafluprost) using the FDA's Adverse Event Reporting System (FAERS) database.
- - It involves a detailed statistical analysis of adverse event data, revealing that eye disorders, particularly iris hyperpigmentation and corneal irritation, are significant issues associated with these drugs.
- - The findings indicate that adverse events occur differently over time across the medications, with latanoprost leading to longer onset times compared to bimatoprost, although the data can't definitively imply cause and effect.
Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis.
Clin Exp Ophthalmol
October 2024
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Background: To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. 'Long-term' is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).
Methods: This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs.
Study of polymer component migrated in medicinal product from transportation packaging component: A systematic assessment beyond regulatory expectations.
J Pharm Sci
December 2024
R & D Center, Indoco Remedies Limited, TTC, MIDC Industrial Area, Thane Belapur Road, Rabale, Navi Mumbai 400701, India.
Article Synopsis
- LDPE bottles were selected as the container closure system for packaging Latanoprost ophthalmic solution, with an alternative manufacturer also providing similar bottles for evaluation.
- An extractables and leachable (E&L) study along with a stability program assessed the quality of the solution in both sets of bottles, revealing an unknown impurity in one batch.
- Further investigation identified the impurity as Epsilon-caprolactam, a leachable from the transportation packaging, highlighting the need to consider the entire supply chain in leachability assessments.
Topical insulin to treat a conjunctival defect after glaucoma surgery: A case report.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada.
Purpose: Insulin has been postulated as a novel and effective treatment for re-epithelialization of the ocular surface and different pathologies have been suggested as possible indications.
Observations: A 69-year-old diabetic male was referred for a left non-healing conjunctival epithelial defect over the superotemporal scleral patch used in the placement of the Ahmed ClearPath. In the left eye, he was on latanoprost/timolol once daily, prednisolone 1 % once daily and tobramycin/dexamethasone ointment at night.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!